Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

被引：3
|
作者：
Rifkin, Robert M. [1 ]
Sharman, Jeff P. [2 ]
Fowler, Jessica [3 ]
Lin, Thomas S. [3 ]
Thomson, Brian [4 ]
Berdeja, Jesus G. [5 ]
机构：
[1] US Oncol Res, Rocky Mt Canc Ctr, Denver, CO USA
[2] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
[3] Johnson & Johnson Innovat Med, Horsham, PA USA
[4] Janssen Pharmaceut, Horsham, PA USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185257
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
    Hailin Chen
    Tengteng Yu
    Liang Lin
    Lijie Xing
    Shih-Feng Cho
    Kenneth Wen
    Kimberly Aardalen
    Adwait Oka
    Joni Lam
    Mike Daley
    Haihui Lu
    Nikhil Munshi
    Kenneth C. Anderson
    Yu-Tzu Tai
    Blood Cancer Journal, 12
  • [22] Promising real-world data of treatment with two BCMA-targeting bispecific T-cell engagers in extensively pretreated myeloma patients
    Strifler, S.
    Wendelin, K.
    Hefter, C.
    Soldatenko, N.
    Morgenstern, N.
    Illing, S.
    Starke, M.
    Dressler, S.
    Gaertner, J.
    Schaefer-Eckart, K.
    Knop, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 313 - 313
  • [23] γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation
    Chen, Hailin
    Yu, Tengteng
    Lin, Liang
    Xing, Lijie
    Cho, Shih-Feng
    Wen, Kenneth
    Aardalen, Kimberly
    Oka, Adwait
    Lam, Joni
    Daley, Mike
    Lu, Haihui
    Munshi, Nikhil
    Anderson, Kenneth C.
    Tai, Yu-Tzu
    BLOOD CANCER JOURNAL, 2022, 12 (08)
  • [24] Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
    Mailankody, Sham
    Matous, Jeffrey V.
    Chhabra, Saurabh
    Liedtke, Michaela
    Sidana, Surbhi
    Oluwole, Olalekan O.
    Malik, Shahbaz
    Nath, Rajneesh
    Anwer, Faiz
    Cruz, Jose Carlos
    Htut, Myo
    Karski, Erin E.
    Lovelace, Wade
    Dillon, Myles
    Butz, Eric
    Ying, Wendy
    Balakumaran, Arun
    Kumar, Shaji K.
    NATURE MEDICINE, 2023, 29 (2) : 422 - 429
  • [25] Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
    Sham Mailankody
    Jeffrey V. Matous
    Saurabh Chhabra
    Michaela Liedtke
    Surbhi Sidana
    Olalekan O. Oluwole
    Shahbaz Malik
    Rajneesh Nath
    Faiz Anwer
    Jose Carlos Cruz
    Myo Htut
    Erin E. Karski
    Wade Lovelace
    Myles Dillon
    Eric Butz
    Wendy Ying
    Arun Balakumaran
    Shaji K. Kumar
    Nature Medicine, 2023, 29 : 422 - 429
  • [26] Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
    Janardan, Abhishek
    Lindsay, Hammons
    Szabo, Aniko
    Bhatlapenumarthi, Vineel
    Annyapu, Evanka
    Dhakal, Binod
    Narra, Ravi Kishore
    Al Hadidi, Samer
    Radhakrishnan, Sabarinath Venniyil
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Siegfried, Janz
    Zangari, Maurizio
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Chakraborty, Rajshekhar
    Schinke, Carolina D.
    Mohan, Meera
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
    Hammons, Lindsay
    Szabo, Aniko
    Janardan, Abhishek
    Bhatlapenumarthi, Vineel
    Annyapu, Evanka
    Dhakal, Binod
    Al Hadidi, Samer
    Radhakrishnan, Sabarinath Venniyil
    Narra, Ravi
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Janz, Siegfried
    Zangari, Maurizio
    Lentzsch, Suzanne
    van Rhee, Frits
    Crescencio, Juan Carlos Rico
    D'Souza, Anita
    Chakraborty, Rajshekhar
    Mohan, Meera
    Schinke, Carolina
    HAEMATOLOGICA, 2024, 109 (03) : 906 - 914
  • [28] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Madduri, Deepu
    Pacaud, Lida
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
  • [29] A Phase 1/2 study of teclistamab, a humanized BCMA x CD3 bispecific Ab in Japanese patients with relapsed/refractory MM
    Ishida, Tadao
    Kuroda, Yoshiaki
    Matsue, Kosei
    Komeno, Takuya
    Ishiguro, Takuro
    Ishikawa, Jun
    Ito, Toshiro
    Kosugi, Hiroshi
    Sunami, Kazutaka
    Nishikawa, Kazuko
    Shibayama, Kazuhiro
    Aida, Kensuke
    Yamazaki, Hiroshi
    Inagaki, Mitsuo
    Kobayashi, Hisanori
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 222 - 231
  • [30] Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
    Sham Mailankody
    Jeffrey V. Matous
    Saurabh Chhabra
    Michaela Liedtke
    Surbhi Sidana
    Olalekan O. Oluwole
    Shahbaz Malik
    Rajneesh Nath
    Faiz Anwer
    Jose Carlos Cruz
    Myo Htut
    Erin E. Karski
    Wade Lovelace
    Myles Dillon
    Eric Butz
    Wendy Ying
    Arun Balakumaran
    Shaji K. Kumar
    Nature Medicine, 2023, 29 : 3271 - 3271
12345